CDK4

Across TCGA pan-cancer cohorts, CDK4 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated CDK4 data layer compared with 27 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher CDK4 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CDK4 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LSCC show a favorable association.

CCRCC, OV, and PDAC are the cancer types where CDK4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	All	0.845	1.000	<.001	51	view →
OV	DFS	Median	All	0.694	1.000	.028	16	view →
PDAC	OS	Tertile	III,IV	0.858	0.207	.002	15	view →
HNSC	OS	Median	All	0.940	0.991	.022	11	view →
UCEC	OS	Quartile	II,III,IV	0.589	1.000	.040	8	view →
GBM	DFS	Median	All	0.637	0.795	.031	2	view →
LSCC	DFS	Tertile	All	1.000	0.953	.032	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

CDK4–CCRCC (DFS)

Open the CCRCC breakdown →